Further TRK Inhibitor Development
Shubham Pant, MD:Tell me, there are other TRK inhibitors out there. So we talked a little bit about entrectinib you said it got like a breakthrough designation. How does that target the TRK? How is it different from other TRK inhibitors?
David S. Hong, MD:So entrectinib is different than larotrectinib in the sense that it also targets ALK, ROS. And the most recent data that came out were also at ESMO [European Society for Medical Oncology 2018 Congress]. Dr George D. Demetri, MD, presented those data. He’s from Dana-Farber Cancer Institute. And in that dataset there was I think about 55 patients. The response rates were slightly lower than larotrectinib, about 57%. As I shared with you, the actual adverse event profile was a little bit more different. The most common adverse effect being dysgeusia.
Shubham Pant, MD:And that was with entrectinib.
David S. Hong, MD:Yes.
Shubham Pant, MD:So as you said entrectinib followed larotrectinib, you said it’s more for like dizziness or…
David S. Hong, MD:Yes. Fatigue.
Shubham Pant, MD:Fatigue was the big one, yes.
David S. Hong, MD:So what’s also interesting is that in the entrectinib dataset they did reach a median, it’s called duration of response, of around 10 months, which at this point with larotrectinibthe dataset that we have of the 55 patients, the initial dataset—we have not even reached a median duration of response. Over 80% of the patients with larotrectinib do appear to at 1 year still maintain their response.
Shubham Pant, MD:All these seem to be durable responses. That means it’s not like one of those drugs that the response happens and then it goes away.
David S. Hong, MD:Correct. And whether that’s entirely because of larotrectinib or just the biology…
Shubham Pant, MD:The biology of the disease, like in slower growing salivary gland tumors.
David S. Hong, MD:It’s not entirely clear yet. And the numbers are too small I think right now for both the entrectinib and larotrectinib for us to make any clear comparisons. I know there are a lot of people who would like to make comparisons between those.
Shubham Pant, MD:But these are different trials, so you cannot cross-compare trials.
David S. Hong, MD:At this point, yes.
Transcript edited for clarity.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
